{
    "url_original": "https://www.wsj.com/articles/pfizer-forecasts-54-billion-in-2022-sales-from-its-covid-19-vaccine-treatment-11644325656?mod=business_lead_pos3",
    "url": "pfizer-forecasts-54-billion-in-2022-sales-from-its-covid-19-vaccine-treatment-11644325656",
    "title": "Pfizer Forecasts $54 Billion in 2022 Sales From Its Covid-19 Vaccine, Treatment",
    "sub_head": "Vaccine’s success produced step change in pharmaceutical company’s revenue trend",
    "category_1": "Business",
    "category_2": "Earnings",
    "time": "2022-02-08 08:07:00",
    "body": "Pfizer Inc.  said Tuesday that surging sales of its Covid-19 treatment and continued demand for its shots will likely boost the company’s revenue to around $100 billion this year.<br />The pharmaceutical company estimated that sales of Paxlovid, a pill aimed at reducing severe outcomes from the virus, will reach about $22 billion in 2022. Pfizer’s vaccine for the virus will likely add $32 billion in revenue, Pfizer said, an increase from Pfizer’s most recent guidance."
}